Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant GPIIIa and/or variant GPIIb allele
OwnerKeith Schappertinventor
Life of this patent
Estimating the term…
Abstract
The invention provides methods for treating or identifying subjects having a neurological disease or at risk for a neurological disease by determining the presence of a variant GPIIIa and/or GPIIb allele.
Claims15
A method for identifying a subject at risk for a non-Alzheimer's neurological disease consisting of Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, neurofibromatosis, depression, multiple sclerosis, stroke, and multi-infarct dementia, comprising determining the genotype at nucleotide 192 of the GPIIIa gene of SEQ ID NO.:
- 2, wherein the gene encodes a polypeptide with a proline at amino acid position 33 of SEQ ID NO.:
- 4, and/or at nucleotide 2622 of GPIIb of gene of SEQ ID NO.:
- 6, wherein the gene encodes a polypeptide with a serine at amino acid position 843 of SEQ ID NO.:
- 8, of said subject, wherein said genotype is indicative of said subject having an increased risk for said non-Alzheimer's neurological disease.
A method for diagnosing a subject with a non-Alzheimer's neurological disease consisting of Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, neurofibromatosis, depression, multiple sclerosis, stroke, and multi-infarct dementia, comprising determining the genotype at nucleotide 192 of the GPIIIa gene of SEQ ID NO.:
- 2, wherein the gene encodes a polypeptide with a proline at amino acid position 33 of SEQ ID NO.:
- 4, and/or at nucleotide 2622 of the GPIIb gene of SEQ ID NO.:
- 6, wherein the gene encodes a polypeptide with a serine at amino acid position 843 of SEQ ID NO.:
- 8, of said subject, wherein said genotype is indicative of said subject having said non-Alzheimer's neurological disease.
A method for characterizing the genotype of at least one subject involved in a clinical trial of a therapy for the treatment of a non-Alzheimer's neurological disease consisting of Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, neurofibromatosis, depression, multiple sclerosis, stroke, and multi-infarct dementia, comprising determining the genotype at nucleotide 192 of the GPIIIa gene of SEQ ID NO.:
- 2, wherein the gene encodes a polypeptide with a proline at amino acid position 33 of SEQ ID NO.:
- 4, and/or at nucleotide 2622 of the GPIIb gene of SEQ ID NO.:
- 6, wherein the gene encodes a polypeptide with a serine at amino acid position 843 of SEQ ID NO.:
- 8, of said subject.
Dependencies are inferred from the claim text.